Sci Show: Treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care.

Saturday, September 18, 2021

Treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care.

https://ift.tt/3Erkryi via /r/science https://ift.tt/3Cj9n4g

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)